Dose Equivalents for Antipsychotic Drugs: The DDD Method

Schizophrenia Bulletin

Volumn 42, Issue , 2016, Pages S90-S94

  Leucht, Stefan ^a,b,c   Samara, Myrto ^a   Heres, Stephan ^a   Davis, John M ^d,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

antipsychotic drugs; dosage; equivalency; olanzapine; quetiapine; risperidone; schizophrenia

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; HUMAN; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; DRUG THERAPY; PHARMACOLOGY; STANDARDS;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY; HUMANS; PHARMACOLOGICAL PHENOMENA;

EID: 84990882978     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv167     Document Type: Article

References (24)

1. Patel MX, Arista IA, Taylor M, Barnes TR. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res. 2013;149:141-148.
2. Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res. 1974;11:65-69.
3. Woods S W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663-667.
4. Methodology WCCfDS. Guidelines for ATC Classifcation and DDD Assignment 2014. Oslo: World Health Organisation; 2013.[AU:Please provide country name for publisher location for references 4, ]
5. Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis [published online ahead of print November 27, 2009]. SchizophrBull. doi: 10.1093/schbul/sbp149
6. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41:656-663.
7. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther. 2008;46:245-251.
8. Yorston G, Pinney A. Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatric Bulletin. 2000;24:130-132.
9. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychot-ics: the minimum effective dose method. Schizophr Bull. 2014;40:314-326.
10. Leucht S, Samara M, Heres S, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull. 2015;41:1397-1402.
11. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsy-chotic dosing. Am J Psychiatry. 2010;167:686-693.
12. Nosè M, Tansella M, Thornicroft G, et al. Is the defned daily dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol. 2008;23:287-290.
13. Rijcken CA, Monster TB, Brouwers JR, de Jong-van den Berg LT. Chlorpromazine equivalents versus defned daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol. 2003;23:657-659.
14. Sweileh WM, Odeh JB, Shraim NY, Zyoud SH, Sawalha AF, Al-Jabi S W. Evaluation of defned daily dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization. Saudi Pharm J. 2014;22:127-132.
15. Davis JM. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry. 1976;33:858-861.
16. Rey MJ, Schulz P, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol. 1989;4:95-104.
17. Committee JF. British National Formulary. 64 ed. London: Royal Pharmaceutical Society and BMJ Publishing Group Ltd; 2012.
18. Dewan MJ, Koss M. The clinical impact of reported variance in potency of antipsychotic agents. Acta Psychiatr Scand. 1995;91:229-232.
19. Bland JM, Altman DG. A note on the use of the intra-class correlation coeffcient in the evaluation of agreement between two methods of measurement. Comput Biol Med. 1990;20:337-340.
20. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
21. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. In: Kaplan HJ, Saddock BJ, eds. Comprehensive Textbook of Psychiatry. 5th ed. Baltimore: Williams and Wilkins; 1989:1591-1626.
22. Baldessarini RJ, Cohen BM, Teicher MH. Signifcance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988;45:79-91.
23. Casey JF, Bennett IF, Lindley CJ, Hollister LE, Gordon MH, Springer NN. Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorproma-zine, promazine, phenobarbital, and placebo. AMA Arch Gen Psychiatry. 1960;2:210-220.
24. Klein DF, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins; 1969.